The observational study measured how physicians changed treatment plans after seeing HER2DX results and how patients did on the new plans.

If Anixa exercises its rights, Verdi and Anixa will collaborate on trials in the US, while Verdi will continue developing personalized vaccines in Europe.

Merck will pay the Chinese pharma company $200 million upfront and up to $1.77 billion in development, regulatory, and commercial milestone payments.

NEW YORK – Everest Medicines said on Sunday that the US Food and Drug Administration cleared an investigational new drug application (IND) seeking permission to begin studying its mRNA vaccine EVM14 ...

The firm's Heart-2 study of VERVE-102, which is designed to inactivate the PCSK9 gene, is already underway in Canada and the UK.

The company said initial efficacy results from a Phase I trial did not provide a competitive benefit-risk profile in CLDN18.2-positive gastric and gastroesophageal cancer.

Precision Medicine Online's 2024 survey shows biomarker test expansion but low clinical trial enrollment and long wait times ...

The drug was already sold for TTR amyloidosis with polyneuropathy, and now is available to patients with hereditary or wild-type ATTR-CM.

By correcting for ancestral bias in publicly available datasets, PhyloFrame produces better outcomes predictions for ...

Although Eisai decided not to option a HER2-targeted drug under a deal with BlissBio, Angle wants to keep working with the firms to advance its CTC technology.

Findings from the nationwide survey suggest interest in PGx while highlighting areas for UK policymakers to pay attention to, ...

The firm's stock price dropped 27 percent on Tuesday following the news that the young man died from acute liver failure after getting Elevidys.